Core Viewpoint - The A-share market has shown significant structural trends in 2023, with the Shanghai Composite Index breaking through 3800 points in August, leading to accelerated rotation of market hotspots and fluctuating performances across sectors [1] Fund Performance - Hu Zhongyuan, a fund manager at Huashang Fund, has consistently ranked in the top ten for all mixed funds he manages over the past 1, 3, and 5 years, demonstrating strong market understanding and asset allocation skills [1][2] - Specific fund performances include: - Huashang Shuangyi Balanced Mixed A ranked 1st in its category for 1, 3, and 5 years [2] - Huashang Runfeng Flexible Allocation Mixed C ranked 1st over 5 years and in the top five for 1 and 3 years [2] Investment Philosophy - Hu Zhongyuan's investment philosophy prioritizes the risk-reward ratio, focusing on industry comparisons and minimizing alpha in stock selection while adhering to a dual diversification principle in portfolio management [3] - His managed funds, such as Huashang Runfeng Flexible Allocation Mixed A, have achieved significant returns since he took over in March 2019, with 1-year, 5-year, and 7-year returns of 146.96%, 193.05%, and 332.42% respectively [3][4] Investment Strategy - Hu Zhongyuan emphasizes a framework based on industry cycles and win rates, selecting industries with clear upward trends in revenue and profit for allocation [5] - He has successfully executed multiple industry switches, such as moving from liquor and pharmaceuticals to coal and consumer sectors, which have contributed to excess returns [5][6] - His strategy includes a dual approach of "industry diversification + stock diversification," which helps mitigate overall portfolio volatility [6] Market Outlook - Looking ahead, Hu Zhongyuan is optimistic about the A-share market in 2025, driven by a combination of policy support and liquidity easing, which he believes will lead to a long-term valuation recovery [8] - Key investment areas include artificial intelligence, communication, electronics, and the evolving Chinese pharmaceutical sector, which are expected to present new opportunities [8]